Standard care versus Celecoxib Outcome Trial The SCOT study is a large streamlined safety study designed to compare the cardiovascular and GI safety of celecoxib versus traditional NSAID therapy. Nearly 8,000 patients with arthritis from UK, Denmark, and the Netherlands were recruited from primary care. Recruitment has finished and follow up will continue throughout 2014. Results are expected around autumn 2015. Image Chief Investigator: Prof Tom MacDonald. (PI in Edinburgh Prof Stuart Ralston) Number and location of participating sites (by region/ country): GP practices in Scotland, England, Denmark and the Netherlands. (Edinburgh node had 75 participating GP practices.) EudraCT number: 2007 0000 12-90 Funder: The sponsor (University of Dundee) is receiving funding support from Pfizer Inc. Start and End date of grant award: Edinburgh contract started 16 Nov 2007 and will continue until 2015. Current Status: Published. See the published article - Document European Heart Journal SCOT study (382.15 KB / PDF) Website: www.scottrial.co.uk Contact details: Morag MacLean (Trial Manager) Tel: 0131 537 3846 / email: morag.maclean@ed.ac.uk Janet Thomson (Clinical Trials Physician) Tel: 07850 256 668 / email: janet.thomson@ed.ac.uk ECTU Involvement: Trial management, recruitment, data collection, study physician, research nurses This article was published on 2024-09-24
